

## **CONSOB APPROVES THE LISTING PROSPECTUS PUBLISHED BY FINE FOODS OF ITS ORDINARY SHARES ON THE MTA - STAR SEGMENT**

Verdellino (BG), 7 July 2021

Fine Foods & Pharmaceuticals N.T.M. S.p.A. ("**Fine Foods**" or the "**Company**"), listed on AIM Italia, a multilateral trading system organised and managed by Borsa Italiana S.p.A. ("Borsa Italiana"), announces that today the Commissione Nazionale per le Società e la Borsa ("CONSOB"- National Commission for Companies and the Stock Exchange) by note dated 7 July 2021, ref. no. 0745945/21 approved the listing prospectus (the "**Listing Prospectus**") of Fine Foods Ordinary Shares on the **STAR segment** of the Mercato Telematico Azionario ("MTA") organised and managed by Borsa Italiana S.p.A. Consob's approval of the Listing Prospectus follows the provision with which Borsa Italiana, on 5 July 2021, ordered the listing of Fine Foods ordinary shares on the MTA.

The Listing Prospectus was filed today with CONSOB and published in the form and terms required by law on the Company's website [www.finefoods.it](http://www.finefoods.it), Investor Relations / IPO section, and is available to the public at the registered office in Zingonia - Verdellino, Via Berlino no. 39.

The listing starting date of the Company's ordinary shares on the STAR segment and the simultaneous exclusion from AIM Italia listing shall be established by Borsa Italiana by means of a specific notice. With the same notice, Borsa Italiana, after verifying the existence of the capitalisation and dissemination requirements established by art. 2.2.3 of the Regulation of Markets organised and managed by Borsa Italiana and the relevant Instructions, will attribute the STAR qualification to the Company's shares.

\*\*\*

This press release is available on the Fine Foods website [www.finefoods.it](http://www.finefoods.it), in the Investor Relations/Press Releases section.

\*\*\*

Fine Foods & Pharmaceuticals N.T.M. S.p.A. is an Italian independent CDMO (Contract Development and Manufacturing Organisation). It develops and manufactures contract products for the pharmaceutical and nutraceutical industry; the Fine Foods Group is also active in the cosmetics, biocides and medical devices industries with its recent acquisition of Pharmatek-PMC.

Founded in 1984, from a pharmaceutical and nutraceutical synergy, Fine Foods has been pursuing quality and innovation on behalf of its customers as its primary objective. With € 172 million revenue in 2020 and an 11 per cent CAGR over the last decade, it is a growing and future-oriented company.

The sustainability of the business model and the holistic approach to ESG, together with product innovation, are drivers that will allow the Group to fully develop its intrinsic potential.

\*\*\*

For information:

**Fine Foods & Pharmaceuticals N.T.M. S.p.A.**

*Investor Relations*

tel. +39 035 4821382

[ir@finefoods.it](mailto:ir@finefoods.it)

**Banca Akros S.p.A.**

*Nomad*

Viale Eginardo 29, Milan

[ecm@bancaakros.it](mailto:ecm@bancaakros.it)

**CDR Communication**

*IR Advisor*

Paola Buratti

[paola.buratti@cdr-communication.it](mailto:paola.buratti@cdr-communication.it)

*Media Relations*

Marianna Tremolada

[marianna.tremolada@cdr-communication.it](mailto:marianna.tremolada@cdr-communication.it)